KSE - Delayed Quote KRW

Samsung Biologics Co.,Ltd. (207940.KS)

1,000,000.00

-6,000.00

(-0.60%)

At close: January 10 at 3:30:23 PM GMT+9

Samsung Biologics and LigaChem extend ADC services deal

The partnership will leverage Samsung Biologics' new ADC facility equipped with a 500l reactor.

Pharmaceutical Technology yesterday

207940.KS
-0.60%
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced to extend collaboration with LigaChem Biosciences (KOSDAQ: 141080) to provide antibody-drug conjugate (ADC) services.

PR Newswire 2 days ago

207940.KQ

207940.KS
-0.60%
Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery

Samsung announced today it has invested in Generate: Biomedicines ("Generate") as part of its efforts to drive growth and innovation in the biopharmaceutical sector. The investment was made via the Samsung Life Science Fund, which was created jointly between Samsung Biologics, Samsung C&T, and Samsung Bioepis, and managed by Samsung Venture Investment Corporation. Established in 2021 and worth KRW 240 billion, the fund has invested in biotech companies with promising technologies.

PR Newswire 23 days ago

207940.KQ

207940.KS
-0.60%
Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its continued recognition by the Dow Jones Sustainability World Index (DJSI), a globally recognized benchmark for evaluating the sustainability performance of over 2,500 publicly traded companies.

PR Newswire 25 days ago

207940.KQ

207940.KS
-0.60%
Samsung Biologics hosts ESG event with suppliers to strengthen decarbonization efforts

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its second Supplier ESG Day to share insights on sustainable management and encourage ESG actions among suppliers.

PR Newswire last month

207940.KQ

207940.KS
-0.60%
Samsung Biologics inks $668m manufacturing deal with European pharma

The South Korean CDMO has now partnered with 17 of the world’s top 20 pharma companies, as per the company.

Pharmaceutical Technology last month

207940.KS
-0.60%
Samsung Biologics signs manufacturing deal with European pharmaceutical company

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced a series of manufacturing deals with a Europe-based pharmaceutical company.

PR Newswire last month

207940.KQ

207940.KS
-0.60%
Samsung Biologics earns ISO certifications in recognition of business excellence

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO) today announced it has achieved ISO 37301:2021 certification for the first time. The company also renewed certifications for upgraded ISO 27001:2022 and ISO 27017:2015 standards. The certifications were presented by the British Standards Institution (BSI) during a ceremony held at Samsung Biologics' headquarters.

PR Newswire 2 months ago

207940.KQ

207940.KS
-0.60%
Samsung Biologics reports third quarter 2024 financial results

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the third quarter of fiscal year 2024.

PR Newswire 2 months ago

207940.KQ

207940.KS
-0.60%
Samsung Biologics signs largest manufacturing deal with Asia-based pharmaceutical company

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced today a contract manufacturing deal with an Asia-based pharmaceutical company.

PR Newswire 2 months ago

207940.KQ

207940.KS
-0.60%
Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), launched today a new high-concentration formulation platform to support the development and manufacturing of high-dose biopharmaceuticals.

PR Newswire 2 months ago

207940.KQ

207940.KS
-0.60%
Samsung Biologics launches development platforms for enhanced therapeutic efficacy

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), launched today a series of proprietary development platforms as part of continued efforts to ensure high-quality development and provide client-tailored services.

PR Newswire 3 months ago

207940.KQ

207940.KS
-0.60%
Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced today that the company has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner.

PR Newswire 5 months ago

207940.KQ

207940.KS
-0.60%
Samsung Biologics Reports First Quarter 2024 Financial Results

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024.

PR Newswire 8 months ago

207940.KS
-0.60%
Samsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC)

Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung's investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code.

PR Newswire 9 months ago

207940.KS
-0.60%
Q4 2023 Rapid Micro Biosystems Inc Earnings Call

Q4 2023 Rapid Micro Biosystems Inc Earnings Call

Thomson Reuters StreetEvents 10 months ago

RPID

207940.KS
-0.60%
Samsung Biologics awarded Leadership status by CDP for climate action efforts

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that it has received the Leadership status and A- rating from the Carbon Disclosure Project (CDP).

PR Newswire 10 months ago

207940.KS
-0.60%
Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced it has signed a partnership agreement with LegoChem Biosciences (KOSDAQ: 141080), a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.

PR Newswire 10 months ago

207940.KS
-0.60%
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2023 Financial Results

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced robust financial results for the fourth quarter and fiscal year 2023.

PR Newswire 11 months ago

207940.KS
-0.60%
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that the company was awarded the EcoVadis' Platinum Sustainability Rating, the highest recognition given, for the company's sustainability management.

PR Newswire 11 months ago

207940.KS
-0.60%

Performance Overview

Return	207940.KS	KOSPI Composite Index
YTD	+5.37%	+4.85%
1-Year	+34.05%	-1.03%
3-Year	+20.89%	-14.04%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Samsung Biologics Co.,Ltd. (207940.KS)

Samsung Biologics and LigaChem extend ADC services deal

Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development

Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery

Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index

Samsung Biologics hosts ESG event with suppliers to strengthen decarbonization efforts

Samsung Biologics inks $668m manufacturing deal with European pharma

Samsung Biologics signs manufacturing deal with European pharmaceutical company

Samsung Biologics earns ISO certifications in recognition of business excellence

Samsung Biologics reports third quarter 2024 financial results

Samsung Biologics signs largest manufacturing deal with Asia-based pharmaceutical company

Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development

Samsung Biologics launches development platforms for enhanced therapeutic efficacy

Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner

Samsung Biologics Reports First Quarter 2024 Financial Results

Samsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC)

Q4 2023 Rapid Micro Biosystems Inc Earnings Call

Samsung Biologics awarded Leadership status by CDP for climate action efforts

Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing

Samsung Biologics Reports Fourth Quarter & Fiscal Year 2023 Financial Results

Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating

Performance Overview